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Hypertrophic cardiomyopathy (HCM) is the most common mendelian heart disease,
with a prevalence of 1/500. HCM is a primary cause of sudden death, due to an
heightened risk of ventricular tachyarrhythmias that often occur in young asymptomatic
patients. HCM can slowly progress toward heart failure, either with preserved or
reduced ejection fraction, due to worsening of diastolic function. Accumulation of
intra-myocardial fibrosis and replacement scars underlies heart failure progression
and represents a substrate for sustained arrhythmias in end-stage patients. However,
arrhythmias and mechanical abnormalities may occur in hearts with little or no fibrosis,
prompting toward functional pathomechanisms. By studying viable cardiomyocytes and
trabeculae isolated from inter-ventricular septum samples of non-failing HCM patients
with symptomatic obstruction who underwent myectomy operations, we identified that
specific abnormalities of intracellular Ca2+ handling are associated with increased
cellular arrhytmogenesis and diastolic dysfunction. In HCM cardiomyocytes, diastolic
Ca2+ concentration is increased both in the cytosol and in the sarcoplasmic reticulum
and the rate of Ca2+ transient decay is slower, while the amplitude of Ca2+-release is
preserved. Ca2+ overload is the consequence of an increased Ca2+ entry via L-type
Ca2+-current [due to prolongation the action potential (AP) plateau], combined with a
reduced rate of Ca2+-extrusion through the Na+/Ca2+ exchanger [due to increased
cytosolic (Na+)] and a lower expression of SERCA. Increased late Na+ current (INaL)
plays a major role, as it causes both AP prolongation and Na+ overload. Intracellular
Ca2+ overload determines an higher frequency of Ca2+ waves leading to delayed-
afterdepolarizations (DADs) and premature contractions, but is also linked with the
increased diastolic tension and slower relaxation of HCM myocardium. Sustained
increase of intracellular [Ca2+] goes hand-in-hand with the increased activation of
Ca2+/calmodulin-dependent protein-kinase-II (CaMKII) and augmented phosphorylation
of its targets, including Ca2+ handling proteins. In transgenic HCM mouse models, we
found that Ca2+ overload, CaMKII and increased INaL drive myocardial remodeling since
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the earliest stages of disease and underlie the development of hypertrophy, diastolic
dysfunction and the arrhythmogenic substrate. In conclusion, diastolic dysfunction and
arrhythmogenesis in human HCM myocardium are driven by functional alterations at
cellular and molecular level that may be targets of innovative therapies.
Keywords: cardiac hypertrophy, ion channels, ranolazine, arrhythmias, afterdepolarization, calmodulin kinase
(CaMKII), T-tubules, beta adrenergic
INTRODUCTION: ARRHYTHMIC
SUBSTRATE IN HCM, FROM TISSUE TO
THE SINGLE MYOCYTE
Hypertrophic cardiomyopathy (HCM) is the most common
monogenic inheritable heart disease (Maron et al., 2000; Gersh
et al., 2011; Authors/Task Force Members et al., 2014), with a
prevalence of 1:500. HCM is a leading cause of sudden cardiac
death in the young (Maron et al., 2000) and a prevalent cause
of heart failure and stroke in all age groups (Maron et al., 2003).
Mutations in genes coding for sarcomeric proteins are found in
over 60% of patients with HCM, the most commonly involved
genes being MYH7 (β-myosin heavy-chain) and MYBPC3
(cardiac myosin-binding protein-C). Increased ventricular
arrhythmogenesis is one of the main pathophysiological features
of this disease (Olivotto et al., 2009) and is responsible for
the heightened risk of lethal arrhythmias in HCM patients.
Despite being only mildly symptomatic in about 2/3 of patients
(Maron et al., 2016), HCM can slowly progress toward heart
failure, either with preserved or reduced ejection fraction, due
to worsening of diastolic and/or systolic function (Olivotto
et al., 2012). Accumulation of intra-myocardial fibrosis and
replacement scars underlies heart failure progression and
represents a substrate for sustained arrhythmias (Galati et al.,
2016). Late gadolinium enhancement (LGE) at cardiac magnetic
resonance, an index of cardiac fibrosis, is widely used to
stratify the severity of disease progression (Authors/Task Force
Members et al., 2014) and to help defining the risk of lethal
arrhythmias and terminal heart failure (Chan et al., 2014).
However, LGE only identifies extensive replacement scars and
well predicts the risk of arrhythmias only at the advanced
stages of the disease (Chan et al., 2014). Replacement fibrosis
in HCM appears to be related with local myocardial ischemia,
caused by microvascular dysfunction (Sotgia et al., 2008), as
myocardial tissue in regions with severe microvascular ischemia
is slowly replaced by collagen. The degree of microvascular
dysfunction, as assessed by positron emission tomography
with labeled ammonia measuring the reduction of local
myocardial blood flow, is related with patient outcome,
including the risk of arrhythmias at advanced disease stages
(Cecchi et al., 2003). Replacement fibrosis and microvascular
ischemia are strongly related with the risk of ventricular
arrhythmias because they create a stable substrate for reentry
circuits, the main drivers of sustained ventricular arrhythmias
(Pogwizd and Corr, 1987). In order for a reentry circuit to be
established, an area of conduction block adjacent to a region of
slower, unidirectional conduction is needed: indeed, in HCM
myocardium, patchy replacement fibrosis generates areas of
no-conduction, while the surrounding ischemic regions (due
to microvascular dysfunction) cause slower, altered conduction,
and transient local alterations of repolarization (Hurtado-de-
Mendoza et al., 2017). Following these observation, the simplest
conclusion would be that structural left ventricular remodeling
at macroscopic myocardial level, featuring replacement fibrosis
and microvascular dysfunction, is the main determinant of
arrhythmias in HCM. However, a clear relationship between
fibrosis (measured with LGE), microvascular dysfunction
(measured by PET) and arrhythmic risk is observed only in the
minority of patients (10–15%) that experience a slow progression
toward end-stage HCM, an highly arrhythmogenic condition
not unlike terminal ischemic heart failure, thus requiring
aggressive preventive strategies (Priori et al., 2015). On the
contrary, the majority of sudden cardiac death events due to
lethal ventricular arrhythmias occur in patients at earlier stages
of disease progression, often in the absence of marked structural
abnormalities besides left-ventricular (LV) hypertrophy, also
in very young patients (Maurizi et al., 2018). In early stages of
hypertrophic cardiomyopathies, replacement scars are absent
and only microscopic intramyocardial fibrosis is present, and
its extent can be assessed by CMR using T1-mapping (Dass
et al., 2012) or extracellular volume (ECV) measurements
with gadolinium contrast, both altered even before the onset
of hypertrophy in HCM-mutation carriers (Ho et al., 2013).
However, the link between the degree of ECV expansion and
the risk of arrhythmias in early stage HCM is still uncertain
(Avanesov et al., 2017). Therefore, arrhythmias in HCM cannot
be the sole consequence of the substrate for re-entry circuits
at tissue level. On the contrary, the main determinants of
arrhythmogenesis in HCM are to be found within the affected
cardiomyocytes, a consequence of the alterations of ion currents
and intracellular Ca2+ handling that occur as a part of HCM-
related ventricular cardiomyocyte remodeling (Coppini et al.,
2013; Coppini et al., 2017; Ferrantini et al., 2017; Ferrantini
et al., 2018). Indeed, from a pathophysiological standpoint,
the vast majority of ventricular tachycardia episodes begin
with one or more premature ectopic ventricular beats (Ulus
et al., 2013). Premature ventricular activations are essential
to initiate the abnormal rotating conduction of the re-entry
circuits in the presence of an appropriate substrate. Even
in the presence of extended structural alterations, such as
large scars and diffuse interstitial fibrosis, ectopic premature
activations initiating in abnormal cardiomyocytes could be
essential triggers to initiate the re-entry that is then maintained
by the structural substrate. Interestingly, ectopic activity is the
primary event producing local unidirectional block, which is
an essential prerequisite for the establishment of a re-entry
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circuit. Ectopic ventricular beats are very common in HCM
patients (Adabag et al., 2005) and originate from the premature
spontaneous premature activation of a group of adjacent
synchronized ventricular cardiomyocytes within the ventricular
mass, which is then propagated to the whole surrounding
ventricular mass, often in a chaotic and unpredictable manner
(Sato et al., 2009). Early- and delayed- afterdepolarizations
are the cellular arrhythmic events that may result into the
spontaneous generation of premature action potentials in
the affected cardiomyocytes. The following part of this
review will illustrate how an increased likelihood of early
and delayed after-depolarizations in HCM cardiomyocytes
is a consequence of specific alterations of ion currents and
intracellular Ca2+-handling.
MATERIALS AND METHODS
Most of the results presented in the figures were previously
published in Coppini et al. (2013) and in Ferrantini et al.
(2018). Previously unpublished results are presented in
Figures 3, 4. Cardiomyocytes and intact trabeculae were
freshly isolated as previously described (Coppini et al.,
2013; Ferrantini et al., 2018), using surgical upper inter-
ventricular septum samples excised from HCM patients
who underwent myectomy operation for the relief of severe
symptoms due to obstruction of the LV outflow tract.
Notably, all recruited patients had preserved systolic function
but impaired diastole and most of them have a history of
documented non-sustained ventricular tachycardia at Holter
monitoring. The experimental protocols were approved by
the ethical committee of Careggi University-Hospital of
Florence (2006/0024713, renewed May 2009; 2013/0035305).
In single cardiomyocytes, APs and Ca2+ transients were
simultaneously measured using combined patch-clamp and
Ca2+-fluorescence measurements, during stimulation at
different frequencies. Cell capacitance was measured in
voltage-clamp mode. Isometric force was measured from intact
trabeculae during electrical field stimulation. Cells/trabeculae
were exposed to test drugs for at least 5 min prior to recordings.
Number of cells/trabeculae for each comparison, as well as
the statistical tests used, are indicated in the respective figure
legends.
REMODELING OF ION CURRENTS IN
HCM CARDIOMYOCYTES
Hypertrophic cardiomyopathy (HCM) cellular pathophysiology
is characterized by the interplay between primary alterations
(direct consequences of causal sarcomeric mutations
altering myofilament function) and a large number of
secondary myocardial modifications, comprising cellular
electrophysiological remodeling (changes in transmembrane
currents) and alterations of intracellular Ca2+ handling [Ca2+
transients and diastolic (Ca2+)] (Coppini et al., 2013; Coppini
et al., 2017; Ferrantini et al., 2017; Ferrantini et al., 2018). Due
to the profound electrophysiological differences between mouse
and human cardiomyocytes, studies conducted on transgenic
rodent models did not help to identify the features if ion-current
remodeling occurring in HCM myocardium (van der Velden
et al., 2015). To overcome this limitation, we investigated
the abnormalities of electrical function, Ca2+ handling and
contraction of human HCM myocardium as coexisting
contributing factors for contractile dysfunction and arrhythmias
in this disease (Coppini et al., 2013). We used isolated myocytes
and intact trabeculae from fresh myocardial samples from the
interventricular septum of HCM patients undergoing surgical
myectomy operation for refractory symptoms related to severe
obstruction of the left ventricular outflow tract, compared
with septal samples from non-hypertrophic surgical patients
(Coppini et al., 2013; Ferrantini et al., 2018). Overall, we
performed patch-clamp and ion-fluorescence studies in over
200 cardiomyocytes from 43 HCM patients (Coppini et al.,
2013; Ferrantini et al., 2018). Results of patch clamp studies in
isolated ventricular cardiomyocytes showed that the duration
of action potentials (APD), recorded at various pacing rates,
was significantly prolonged in cardiomyocytes from HCM
cardiomyocytes, with regards to controls (Figure 1A). As
expected, prolongation of APD was associated with prolonged
QTc in patients from the HCM cohort (average QTc = 470 ms).
Of note, a recent large multi-center observational study on HCM
patients suggested that mild QT prolongation is a common
observation in those patients (Johnson et al., 2011). Prolonged
APD was the main determinant of the increased risk of early
afterdepolarisations (EADs) (Antzelevitch and Belardinelli,
2006), that is, spontaneous depolarisations occurring before
the end of the repolarization phase: the occurrence of this
type of cellular arrhythmias was 6-fold more frequent in HCM
vs. control cardiomyocytes (Figure 1B). Interestingly, the
frequency of EADs and the degree of APD prolongation went
hand in hand with the incidence of ventricular arrhythmias in
patients: patients whose cells show markedly prolonged APDs
had a higher rate of documented non-sustained ventricular
tachycardia at 24 h ECG (Coppini et al., 2013; Figure 1C).
APD prolongation in HCM cardiomyocytes is caused by a
combination of decreased repolarizing potassium currents and
increased depolarizing (Ca2+ and Na+) currents: transient
outward K+ current (Ito), inward-rectifier current (IK1),
as well as delayed rectifier K+ currents were significantly
reduced, while both L-Type Ca2+ current (ICaL) and late Na+
current (INaL) were increased in HCM cells, as compared to
control cardiomyocytes (Coppini et al., 2013; Figures 1D–H).
Pathological changes of the density of ion currents in HCM
cardiomyocytes were caused by different mechanisms. The
reduced density of potassium currents in HCM cardiomyocytes
was the consequence of the lower levels of expression of K+
channel genes (Figures 1D,E), as observed in several human
and animal models of cardiac hypertrophy and heart failure
(Ravens and Cerbai, 2008), including heart failure with preserved
ejection fraction (HFpEF) (Cho et al., 2017). In line with other
models of LV hypertrophy and diastolic dysfunction (Cho
et al., 2017), in human HCM myocardium the ion-channel
genes with the most severely depressed expression were Ito
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FIGURE 1 | Remodeling of ion currents in HCM cardiomyocytes (A) Superimposed representative action potentials recorded during stimulation at 0.2 Hz from HCM
and control cardiomyocytes. (B) Representative recording from an HCM cardiomyocyte paced at 0.2 Hz, showing EADs. Black arrows mark stimuli. Orange arrows
mark EADs. (C) Occurrence of EADs in 23 cells from patients without NSVT (NSVT−) and 29 from patients with NSVT (NSVT+). (D) Representative traces (left, top
panel control, bottom panel HCM) and average Ito activation curves from control and HCM cardiomyocytes (right panel). (E) RNA expression of potassium current
genes, relative to GAPDH in control (N = 11, gray) and HCM (N = 15, black) samples. (F) Left: representative ICaL traces at different voltages. Right: ICaL activation
curves. (G) Superimposed normalized ICaL recordings at 0 mV. (H) Protein expression of ICaL and I Na main channel subunits (Cav1.2 and Nav1.5). (J) Representative
INaL traces from control and HCM cardiomyocytes. (K) Ranolazine inhibits INaL in HCM cardiomyocytes: representative INaL traces from an HCM cardiomyocyte
during depolarization to −20 mV in the absence (Basal) or presence of Ran. (I) Action potentials at 0.2 Hz from an HCM cardiomyocyte before (Basal) and after
exposure to 10 µmol/L ranolazine (Ran). Modified from Coppini et al., 2013 (ref. 19).
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and IK1 (Coppini et al., 2013): this might be a consequence of
the increased activity of Ca2+/calmodulin-dependent protein-
kinase II (CaMKII) in HCM cardiomyocytes (Coppini et al.,
2013), which is able to down-regulate Ito and IK1 currents
by reducing the expression of functional channels (Wagner
et al., 2009). Moreover, the down-regulation of IK1 (Kir2.1)
may also be related with the increased expression of micro-
RNA miR-1 (Yang et al., 2007) observed in HCM specimens
(Coppini et al., 2013). The small increase of ICaL density in
HCM cardiomyocytes is likely determined by the slightly
higher expression of CACNA1.2 gene and CaV1.2 protein
(Figures 1F–H). In addition, the inactivation kinetics of
ICaL is markedly slower in HCM vs. control cardiomyocytes
(Coppini et al., 2013; Ferrantini et al., 2018; Figure 1G),
contributing to prolong ICaL activation during the AP plateau,
thus delaying repolarization. Interestingly, we found that the
slower inactivation of ICaL observed in HCM cardiomyocytes
may be related with the increased phosphorylation of L-type
Ca2+ channel β-subunit by CaMKII (Hudmon et al., 2005),
observed in HCM myocardium (Figure 3). Finally, INaL was
consistently increased in all studied HCM myocytes: INaL
integral (estimating the total Na+ flow upon a single current
activation) was 2–3 times larger in HCM as compared with
control cells (Figure 1J). As INaL is the slowly inactivating
or non-inactivating component of Na+ current that remains
active as a depolarizing current during the AP plateau, it
directly contributes to prolong APD in HCM cardiomyocytes,
as previously shown in human and animal models of cardiac
hypertrophy and heart failure (Maltsev et al., 1998; Pieske
and Houser, 2003; Pogwizd et al., 2003). The aforementioned
changes in Ca2+, late Na+ and K+ current densities were
quantitatively introduced into validated mathematical models
of human ventricular myocyte (Grandi et al., 2010; Coppini
et al., 2013; Passini et al., 2016): these studies confirmed that
the observed ion current changes are sufficient to explain the
prolongation of APD in human HCM cardiomyocytes. Also,
modeling studies suggested that increased INaL plays a pivotal
role as determinant of APD prolongation and EADs in HCM
(Passini et al., 2016), as repolarization reserve is extremely
reduced by the down-regulation of K+ currents. In support
of this hypothesis, we studied the effects of INaL inhibition
by ranolazine (Antzelevitch et al., 2004) or GS-967 (Sicouri
et al., 2013) (a potent and selective INaL blocker) in HCM
cardiomyocytes (Coppini et al., 2013; Ferrantini et al., 2018):
INaL inhibition significantly reduced APD by approximately
30% in all HCM cardiomyocytes (Figure 1). Of note, ranolazine
(at the clinically relevant concentration of 10 µM) and GS-967
(at 0.5 µM) reduced INaL by 70% in HCM cardiomyocytes.
Consistently, the likelyhood of EADs in HCM cardiomyocytes
was nearly halved by ranolazine or GS-967. In agreement with
the increased role of INaL as a determinant of APD in the
presence of an impaired repolarization reserve, the efficacy of
ranolazine in shortening APD was more pronounced at low
pacing frequencies and in cells with a longer APD at baseline.
Studies in a mathematical cardiomyocyte model (Passini et al.,
2016) confirmed that inhibition of 70% of INaL in HCM myocytes
is sufficient to reduce APD, abolish EADs and reduce APD
dispersion, as experimentally observed with pharmacological
blockers.
REMODELING OF Ca2+ HANDLING IN
HCM CARDIOMYOCYTES
Notwithstanding the large variabilities observed among different
disease models, the common feature that is described in all
transgenic animal models, human samples and cellular models of
HCM is the sustained increase of diastolic intracellular calcium
concentration [(Ca2+)]i within ventricular cardiomyocytes
(Knollmann et al., 2003; Haim et al., 2007; Ashrafian et al.,
2011; Fraysse et al., 2012; Lan et al., 2013). The increase
of [Ca2+]i is likely to be a direct consequence of some of
the sarcomere mutations that cause the disease and thus it
may among the first pathological changes in the hearts of
HCM-mutation carriers. Indeed, the majority of HCM-related
mutations cause an increase of the Ca2+-sensitivity of the
myofilaments and determine an increased ATP-consumption by
the cardiac sarcomeres (Ashrafian et al., 2011), thus reducing
the energetic efficiency of force production by the myocardium.
Both these primary sarcomeric changes are associated with an
increase of [Ca2+]i: the increased myofilament Ca2+- sensitivity
determines a slower release of Ca2+ from Troponin-C that in
turn prolongs the decay of Ca2+-transients and leads to elevated
diastolic [Ca2+]i (Baudenbacher et al., 2008). ATP depletion
caused by the reduced efficiency of mutated myofilaments
can reduce the function of the sarcoplasmic reticulum Ca2+-
ATPase (SERCA), thus reducing the rate of Ca2+ reuptake
from the cytosol during relaxation (Ashrafian et al., 2003).
Regardless of the cause that primarily increases [Ca2+]i, the
complex remodeling of the Ca2+-handling apparatus in the
cardiomyocytes of HCM hearts determines a global alteration
of intracellular Ca2+ fluxes, ultimately contributing to aggravate
Ca2+ overload in the cytosol and in the sarcoplasmic reticulum
(SR) (Figure 2).
In human HCM cardiomyocytes, abnormalities of APD
and ion current were paralleled by marked alterations of
intracellular Ca2+ handling (Coppini et al., 2013; Ferrantini
et al., 2018), as studied by virtue of fluorescence measurements
using Ca2+-sensitive dyes. Ca2+ transient amplitude was similar
in HCM and control myocytes. Conversely, Ca2+ transient
kinetics was significantly slower and intracellular diastolic
Ca2+ concentration ([Ca2+]i) was higher in HCM cells as
compared to control cardiomyocytes, especially at higher
rates of stimulation (Figures 2A–C). The elevated [Ca2+]i
contributed to the abnormally high rate of spontaneous Ca2+
releases from the SR observed in HCM myocytes, resulting in
diastolic Ca2+-waves and delayed after-depolarizations (DADs),
thus contributing to cellular arrhythmogenesis (Figure 2D).
Additionally, SR Ca2+ content was slightly increased in HCM
cardiomyocytes (Figure 2F), at variance with human and animal
models of heart failure with reduced systolic function, where
decreased SR Ca2+ content and Ca2+ transients amplitude
are common observations (Beuckelmann et al., 1992; Shan
et al., 2010). The altered Ca2+ fluxes in HCM myocytes
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FIGURE 2 | Remodeling of Ca2+ handling in HCM cardiomyocytes. (A) Superimposed representative Ca2+ i transients recorded during stimulation at 0.2 Hz. from
control and HCM cardiomyocytes. (B) Continuous recordings of Ca2+ i transients elicited at 0.2, 0.5, and 1 Hz frequency of stimulation, from a control (above) and
an HCM (below) cardiomyocyte. (C) Average diastolic Ca2+ i fluorescence levels at increasing pacing frequencies. (D) Representative recording from an HCM
cardiomyocyte, showing DADs, occurring in response to spontaneous Ca2+ release (calcium waves). Black arrows mark stimuli. Orange arrows mark DADs.
(E) Ca2+ fluorescence traces during the protocol to measure SR Ca2+ content with caffeine: superimposed normalized caffeine-induced calcium transients from
HCM and control cardiomyocytes. (F) SR Ca2+ content (left) in control and HCM cardiomyocytes. (G) Protein expression of NCX1, SERCA2a, RYR2 and PLB in
HCM (N = 10) and control (N = 10) specimens. (H) Superimposed representative Ca2+ i transients at 0.2 Hz from an HCM cardiomyocyte at baseline and with
ranolazine. (J) Trains of Ca2+ i transients elicited at 0.2, 0.5, and 1 Hz in an HCM myocyte before (left) and following (right) exposure to Ran. (K) Representative
traces of ANG-II florescence (intracellular sodium) during diastole, recorded at steady state stimulation of 0.2, 0.5, and 1 Hz in the absence (black) and presence (red)
of 10 µM Ran. (I) Representative trains of action potentials elicited at 0.5 Hz at baseline (black traces) and in the presence of GS-967 0.5 µM (red traces). Early
after-depolarizations (EADs) are marked by arrows. (L) Representative trains of action potentials elicited at 0.5 Hz. Delayed after-depolarizations (DADs) are marked
by arrows. Modified from Coppini et al. (2013) and from Ferrantini et al. (2018).
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FIGURE 3 | Increased CaMKII activity underlies electro-mechanical
remodeling in HCM cardiomyocytes: acute effects of CaMKII block with
Autocamtide 2-related inhibitory peptide II (AIP II) on Ca2+ transients and
twitch force. (A) Right: Representative Western blots (above) for total CaMKII,
(Continued)
are the result of several concurrent alterations: (i)increased
amplitude and slower inactivation kinetics of L-Type Ca2+-
current (see above), (ii)reduced expression of SERCA and
reduced SERCA/phospholamban ratio (Figure 2G), (iii)loss or
disorganization of t-tubules (see below), (iv) increase leakage of
Ca2+ from the SR, and (v)abnormal function of the Na+/Ca2+
exchanger (NCX). The latter is the consequence of the increased
intracellular concentration of Na+ ([Na+]i). In agreement
FIGURE 3 | Continued
phosphorylated CaMKII at threonine 287 (p-CaMKII), phosphorylated L-type
Ca2+ channel β2 subunit at threonine 498 (p-LTCCb2), phosphorylated
phospholamban at threonine 17 (p-PLB) and phosphorylated ryanodine
receptor 2 at serine 2814 (p-RyR2). Average values from septum of control
(n = 10) and HCM patients (n = 10) are reported below. Left: Representative
Western blots (above) and mean values (below) for Co-IP of Nav1.5 with
CaMKII from control (n = 10) and HCM patients (n = 10), probed with
antibodies for Nav1.5, p-CaMKII and total CaMKII. (A,B) For each protein, 5
blots representative of the 10 are shown. Relative intensity of individual bands
was quantitated and normalized to GAPDH. The ratio for control was
assigned a value of 1. ∗∗P < 0.01, t-test. Modified from Coppini et al., 2013.
(B) Representative Ca2+ transients recorded from an HCM cardiomyocytes in
the absence and in the presence of AIP II, showing a reduction of diastolic
[Ca2+]i levels upon administration of AIP II. Data from 19 cells from 4 patients
(C) Top: Representative force traces from an HCM trabecula in the absence
and in the presence of AIPII, showing a reduction of diastolic tension after
AIPII and mean diastolic tension at various frequency from 6 HCM trabeculae
(5 patients), in the absence and in the presence of AIP II. Bottom: Normalized
representative force traces highlighting the effects of AIPII on twitch kinetics
and mean data for contraction peak time, at baseline, under AIP II and after
washout of the drug (B,C). #P < 0.05 in paired t-test. Previously unpublished
data.
with these results, we calculated a negative shift of the NCX
reversal potential (ENCX), suggesting increased [Na+]i. Indeed,
we directly observed an increase of [Na+]i in HCM myocytes,
as measured in human HCM myocytes using the Na+-selective
fluorescent dye Asante Natrium Green II (Figure 2K). Based
on this observation, we proposed that enhanced Na+ influx
mediated by the larger INaL leads to a sustained increase in
cytosolic [Na+]i, providing the driving force for an increased
rate of Ca2+ entry trough NCX, as previously observed in
secondary LV hypertrophy (Terracciano et al., 2001), albeitnot
in heart failure. Combined with the increased expression of
NCX and the prolongation of APs, this mechanism leads to an
increased total Ca2+ entry during the plateau of the AP, thus
helping HCM cardiomyocytes to maintain normal SR Ca2+ load,
Ca2+ transients amplitude and contractility (Weisser-Thomas
et al., 2003) despite SERCA down-regulation. This is at variance
with reports on human failing cardiomyocytes (Beuckelmann
et al., 1992), where SERCA down-regulation reduces SR Ca2+
load and Ca2+ release. However, the increased cytosolic [Na+]i
in HCM myocytes also reduces forward-mode NCX activity,
thus determining the observed decrease of Ca2+ extrusion rate
during exposure to caffeine (Figure 2E) and likely contributing
to prolong Ca2+ transient decay and increase diastolic [Ca2+]i,
in combination with the reduced activity of SERCA. Notably,
prolongation of APs likely contributes to reduce Ca2+ extrusion
through the NCX, as the exchanger can effectively work in
forward mode only at diastolic potentials. The central role of the
increased INaL in determining Na+ and Ca2+ overload in HCM
cardiomyocytes is highlighted by the effects of INaL inhibition by
ranolazine or GS-967 (Coppini et al., 2013; Ferrantini et al., 2018).
In human HCM cardiomyocytes, besides shortening APD, INaL
inhibition reduced intracellular [Na+] (Figure 2K), as directly
assessed using fluorescence measurements. The reduction of
[Na+]i shifted ENCX back to positive levels; this in turn led
to a potentiation of the forward-mode activity of the NCX
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(Ca2+ extrusion/Na+ entry), while it decreased the reverse-
mode function (Ca2+ entry/Na+ extrusion). The enhanced Ca2+
extrusion via the NCX resulted in an acceleration of Ca2+-
transient decay, determined a reduction of diastolic [Ca2+]i, and
lessened diastolic [Ca2+]i rise in response to increases of pacing
frequency (Figures 2H–J). In keeping with these observations,
we observed that ranolazine hastened the decay of caffeine-
induced Ca2+ transients and slightly reduced SR Ca2+-content
in HCM cardiomyocytes (Coppini et al., 2013). Interestingly, the
reduction of diastolic [Ca2+]i by ranolazine or GS-967 reduced
the occurrence of spontaneous diastolic Ca2+ waves, DADs and
triggered activity (Figures 2I–L).
Intracellular Ca2+ overload negatively affected diastolic
function in HCM myocardium: kinetics of relaxation was slower
in HCM vs. control trabeculae and diastolic tension was higher,
especially at high stimulation frequencies. Ranolazine and GS-
967, by lowering diastolic [Ca2+]i, accelerated relaxation of
HCM myocardium (Coppini et al., 2013; Ferrantini et al., 2018).
Of note, when used in control myocytes and trabeculae, we
observed none of the effects shown by ranolazine and GS-967
on action potentials, Ca2+-handling and contraction in HCM
myocardium (Coppini et al., 2013; Ferrantini et al., 2018); these
results highlight the selectivity of these compounds for INaL over
peak INa and support the idea that INaL augmentation plays
a leading role in the remodeling of cardiac electro-mechanical
function in HCM.
Most of the abnormalities of Ca2+ handling and contraction
we observed in human cardiomyocytes and trabeculae were
present also in cardiomyocytes isolated from the hearts of
transgenic mice carrying the clinically relevant R92Q mutation of
the Troponin T gene (Coppini et al., 2017; Ferrantini et al., 2017):
these include slower Ca2+-transients, elevated [Ca2+]i, increased
INaL and [Na+]i, as well as impaired relaxation and elevated
diastolic tension. Interestingly, in cardiomyocytes from the R92Q
mouse, ranolazine hastened Ca2+ transients, normalized [Ca2+]i
and [Na+]i and reduced Ca2+-dependent arrhythmias. The
observed antiarrhythmic effect of ranolazine may, at least in part,
depend on the direct stabilization of ryanodine receptors by the
drug (Parikh et al., 2012), which may have contributed to reduce
spontaneous diastolic Ca2+ release and arrhythmogenic Ca2+
waves in human and mouse HCM cardiomyocytes.
ROLE OF CAMKII IN HCM
PATHOPHYSIOLOGY
Sustained activation of the signaling pathways driven by calcium-
calmodulin dependent protein kinase II (CaMKII) appear
to play a central role as a determinant of cardiomyocyte
remodeling and dysfunction in HCM myocardium (Figure 3),
as observed in several human and animal models of cardiac
hypertrophy and heart failure (Ling et al., 2009; Toischer et al.,
2010; Fischer et al., 2013). Sustained activation of CaMKII
in disease conditions is driven by the increase of cytosolic
[Ca2+]I within the cardiomyocyte, as Ca2+-bound calmodulin
is the most important activator of this kinase (Hudmon and
Schulman, 2002). Additionally, enhanced generation of reactive
oxygen species in diseased myocytes, a likely consequence of
myocardial energetic derangement, can be a strong contributor
to CaMKII over-activation in HCM cardiac muscle (Erickson
et al., 2011). Once activated, CaMKII then phosphorylates itself
(at threonine 286 site), thereby prolonging and potentiating its
activated state. In HCM vs. control specimens (Coppini et al.,
2013), CaMKII auto-phosphorylation was increased 3.5-fold
(Figure 3A), indicating increased activity (Lai et al., 1986). This
in turn potentiates the phosphorylation of all the downstream
targets of CaMKII (Toischer et al., 2010; Anderson et al., 2011;
Fischer et al., 2013). CaMKII targets several proteins involved in
the regulation of cardiomyocyte electrophysiology and calcium
fluxes. The observed 2.5-fold higher phosphorylation of cardiac
Na+ channel (NaV1.5) by CaMKII in HCM samples (Figure 3A;
Coppini et al., 2013) may have significantly contributed to
increase INaL in HCM cardiomyocytes (Wagner et al., 2006);
this suggests that CaMKII activation is the most relevant cause
of INaL augmentation in HCM cardiac myocytes, although
additional mechanisms might be involved (e.g., oxidation of
Na+channels) (Lu et al., 1999). The increased phosphorylation
of L-Type Ca2+ channel (Figure 3A) may have contributed
to slow down ICaL inactivation in HCM cells (Hudmon et al.,
2005; Xu et al., 2010). The slower ICaL inactivation may also
be a consequence of the loss of T-tubules observed in HCM
cardiomyocytes (see below) (Brette et al., 2004). Moreover, the
observed 1.5-fold higher CaMKII-dependent phosphorylation
of RyR2 (Figure 3A) may have contributed to increase the
rate of spontaneous releases during diastole (Shannon et al.,
2003) and DADs (Curran et al., 2010) in HCM myocytes.
Finally, the observed 3-fold higher phosphorylation of PLB
at CaMKII site (Figure 3A), via reduced SERCA inhibition,
may have partially counteracted the consequences of reduced
SERCA expression in terms of SR Ca2+ reuptake, ultimately
contributing to maintain SR Ca2+ content and steady state
Ca2+-transient amplitude in HCM cardiomyocytes (Mattiazzi
and Kranias, 2011). In support of the previous observations,
we here tested the effects of the acute inhibition of CaMKII in
HCM cardiomyocytes and trabeculae by using the cell-permeant
version of Autocamtide-related inhibitory peptide II (AIP-II, see
Figures 3B–C). In single human HCM cardiomyocytes, AIP-II
reduced diastolic [Ca2+]i and limited the increase of diastolic
[Ca2+]i at higher stimulation frequencies, without affecting
the amplitude or the kinetics of Ca2+-transients (Figure 3B).
In line with that, when used in intact human HCM while
measuring twitch force, AIP-II reduced diastolic tension and
limited the increase of diastolic tension upon increase of pacing
rate (Figure 3C). Interestingly, AIP-II accelerated time-to-peak
contraction in HCM trabeculae, suggesting that acute inhibition
of CaMKII may directly affect the kinetics of force generation by
the myofilaments.
Besides the direct effects on cardiomyocyte function, CaMKII
is able to alter the expression of genes involved in the
hypertrophic remodeling process of cardiomyocytes, and to
facilitate the production of collagen, the increase of extracellular
matrix volume and the growth of cardiac fibroblasts (Kreusser
and Backs, 2014). We verified that CaMKII participates in
the development and progression of cardiac functional and
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structural phenotype in HCM by studying the transgenic R92Q-
TnT mouse model. In the R92Q-TnT mouse, CaMKII activity,
increased INaL and cardiomyocyte Ca2+ overload go hand in
hand during disease development and are present since the
earliest stages of disease development (Coppini et al., 2017;
Ferrantini et al., 2017). In this mouse model, lifelong treatment
with ranolazine prevented the development of all features
of HCM-specific cardiac phenotype, including LV thickening,
progression of LV diastolic dysfunction and intra-myocardial
fibrosis and the establishment of an arrhythmogenic substrate
(Coppini et al., 2017). The mechanism by which ranolazine
prevents the hypertrophic HCM phenotype is related to the
inhibition of the enhanced INaL, leading to decreased intracellular
[Na+] and diastolic [Ca2+]i, eventually avoiding the pathological
intensification of CaMKII function in treated mice (Coppini
et al., 2017). The reduction of CaMKII-activity in treated
mice prevented the progression of the hypertrophic remodeling
in mutant hearts, thereby reducing the morphological and
functional cardiac HCM-phenotype in mutation-carrier mice.
LOSS OF T-TUBULES IN HCM
CARDIOMYOCYTES
T-tubules (Ferrantini et al., 2013) play a fundamental role in
myocardial function because they allow a quick propagation
of APs within the inner portions of cardiac myocytes. The
simultaneous electrical activation of the whole t-tubular system
allows for a synchronous triggering of Ca2+release from the
SR across the whole myocytes, even the central regions that
are farther away from surface sarcolemma. This is essential to
achieve an homogeneous activation of all myofilaments and thus
a rapid simultaneous shortening of the entire cardiac cell. As a
proof of concept, by acutely disrupting T-tubules trough osmotic-
shock, Ca2+release was rendered asynchronous (Brette et al.,
2005), resulting in a clear impairment of contractile function and
a slower relaxation (Ferrantini et al., 2014). In cardiomyocytes
from animal models of cardiac hypertrophy and heart failure,
a delay of local Ca2+release was observed both in areas where
t-tubules are disrupted (Song et al., 2006) and in regions adjacent
to electrically uncoupled T-tubules (Sacconi et al., 2012; Crocini
et al., 2014). Lyon et al. (2009) studied T-tubular structures in
myocardial specimens from patients with HF caused by different
diseases (i.e., post-ischemic HF, dilated cardiomyopathy and
HCM) and observed a significant reduction of T-tubule density
in all failing human hearts regardless of the underlying disease,
including in end-stage HCM. In a mouse model of HCM we
used Random Access Multi Photon (RAMP) microscopy to
measure the local propagation of APs in the T-tubule and the
correspondent release of Ca2+in the adjacent junctional area by
simultaneously mapping multiple sites of an isolated cell. With
this technique, we found that more than 20% of T-tubules are
unable to propagate AP and the surrounding junctional regions
display a significantly delayed local Ca2+release (Crocini et al.,
2016). In this mouse model, asynchronous intracellular Ca2+
release due to altered T-tubules contribute to slow down Ca2+-
transient kinetics and impair diastolic function.
In all cardiomyocytes subjected to patch-clamp
measurements, we measured cell capacitance, an index of
sarcolemma extension, and compared with cell volume, as
estimated by cell surface (Figure 4A). The ratio between cell
capacitance and volume (surface/volume ratio) was reduced in
HCM vs. control human cardiomyocytes, suggesting reduction
of T-tubules. In addition, we recently performed a preliminary
assessment of the density of T-tubules in cardiomyocytes isolated
from surgical septal samples of 10 HCM patient (Ferrantini
et al., 2018; Figures 4B,C): in all the myocytes studied under
the confocal microscope after membrane fluorescent labeling,
we observed a very low density of T-tubules, much lower than
what is expected in healthy human cardiomyocytes (Lyon et al.,
2009). We previously demonstrated that the loss of t-tubules may
directly contribute to slow down the kinetics of Ca2+ transients
(Ferrantini et al., 2014), thus delaying relaxation, with possible
detrimental effects on diastolic function. However, it is unclear
whether and how loss of t-tubules affects the propensity toward
arrhythmias of HCM cardiomyocytes. Loss of t-tubules could
be protective against arrhythmias because orphan RyR channels
(RyR uncoupled from t-tubules) have a reduced likelihood of
diastolic spontaneous opening (Brette et al., 2005); however,
the rate of Ca2+ waves is increased in human HCM. Loss of
t-tubules leads to reduction of capacitance/volume ratio, thus
increasing conduction velocity in detubulated myocardial tissue:
this effect may prevent the formation of small re-entry circuits.
On the contrary, loss of t-tubules may promote arrhythmias
because it reduces synchronicity of Ca2+ release, thus raising
the likelihood of APD and effective-refractory-period (ERP)
temporal fluctuations (alternans): APD and ERP alternans
facilitate the formation of dynamic reentry circuits (Heinzel et al.,
2011). In support of this, we found that Ca2+ release is indeed
asynchronous in human HCM cardiomyocytes (Figure 4D).
Moreover, loss of t-tubules reduces Ca2+-dependent inactivation
of ICaL, as subsarcolemmal systolic [Ca2+] is lower below surface
sarcolemma than in proximity of T-tubules (Morotti et al.,
2012): indeed, ICaL inactivation is slower in human HCM cells as
compared with controls. Finally, the presence of dysfunctional
residual t-tubules within the myocyte may facilitate spontaneous
Ca2+-release events at SR sites adjacent to those tubules, as we
previously showed in a model of heart failure (Crocini et al.,
2014), increasing the overall risk of Ca2+ waves and DADs.
ABNORMAL RESPONSE OF HCM
MYOCARDIUM TO BETA-ADRENERGIC
STIMULATION
We recently investigated the characteristics and anomalies of
β-adrenergic signaling in the myocardium of HCM patients by
comparing the response of control cardiac muscle to β-adrenergic
stimulation with that observed in HCM cardiomyocytes or
trabeculae (Ferrantini et al., 2018; Figure 5). In particular,
we observed that the mechanical response to the β-adrenergic
agonist isoproterenol (that is, augmentation of twitch force
amplitude and acceleration of relaxation) was qualitatively
similar in HCM and control trabeculae, albeit the kinetics
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FIGURE 4 | The density of T-tubules is markedly low in HCM cardiomyocytes. (A) Left: Representative images of a control (top) and an HCM(bottom) cardiomyocyte,
showing cell hypertrophy in HCM. Right: surface/volume ratio in HCM and control cardiomyocytes;surface is derived from cell capacitance, volume estimated from
cell area. Data from 64 cells (14 patients). Previously unpublished data. (B) 2-photon image recorded in HCM intact tissue after membrane labeling with anepp dyes,
showing a severe reduction of T-tubules. (C)Each cell derives from a different patient sample (ID of the patient is indicated next to the cell in each respective image).
Cells were stained with Di-3-ANEPPDHQ (Thermo-Fisher) and imaged with a Leica Confocal microscope using the 488 nm laser line. Sections were taken at mid
cell. While the outer sarcolemma is well stained in all myocytes, T-tubules are barely visible in most of them and some cells are completely devoid of T-tubules. White
bars equal 10 µm. (D) Recordings of intracellular calcium from an HCM myocytes using a fast camera; right: calcium variations during an elicited electrical activation
in the subsarcolemma and in the cell core. In agreement with the loss of t-tubule, calcium rise in the core is significantly delayed. Previously unpublished data.
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FIGURE 5 | Mechanical and electrical response to β-adrenergic stimulation of HCM myocardium. (A) Representative superimposed force twitches elicited at 0.5 Hz
in control (left) and HCM (right) trabeculae in the absence and presence of Isoproterenol 10−7M (Iso). (B) Isometric tension during steady state stimulation at 0.5 in
the absence and presence of Iso in control and HCM trabeculae. (C) Duration of force twitches (from stimulus to 90% of relaxation) elicited at 0.5 Hz in the absence
and presence of Isoproterenol 10−7M. (D) Percentages of Change in the parameters of twitch kinetics (0.5 Hz) upon exposure to Iso in Control (cyan) and HCM
(green) trabeculae: time from stimulus to peak contraction (peak time) and time from peak to 50% of relaxation (RT50%). (E) Representative superimposed action
potentials elicited at 0.5 Hz in control (left) and HCM (right) cardiomyocytes, in the absence and presence of Iso. (F) Percentages of Change in the parameters of
action potential kinetics upon exposure to Iso in Control (cyan) and HCM (green) cardiomyocytes: time from stimulus to 50% repolarization (APD50%) and time from
peak to 90% of repolarization (APD90%). (G) Representative superimposed L-Type Ca-current traces at baseline (black traces) and in the presence of Iso (green).
(H) L-Type Ca-current inactivation time-constant(left) and density (right) at baseline (black) and with Iso (green) in HCM cells. Modified from Ferrantini et al. (2018).
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of contraction and relaxation remained slower in HCM
myocardium, even upon maximal β-adrenergic activation
(Ferrantini et al., 2018; Figures 5A–D). These results suggest
that the molecular mechanisms responsible for the acceleration
of relaxation upon β-adrenergic activation [i.e., myofilament
Ca2+-desensitization (Sequeira et al., 2013) and phospholamban
phosphorylation (Coppini et al., 2013; Helms et al., 2016)] are
preserved in HCM myocardium.
On the contrary The electrical response to isoprenalin
observed in single HCM cardiomyocytes was profoundly
different as compared with control cardiac cells (Figures 5E–
G). Activation of β-adrenergic receptors physiologically leads
to the enhancement of both ICaL and the slow delayed-rectifier
K+ current (IKs). In healthy human cardiomyocytes the increase
of repolarizing K+ currents prevails over the augmentation of
ICaL (Terrenoire et al., 2005), thus determining a net reduction
of AP duration (Taggart et al., 2003; Figure 5E). In HCM
cardiomyocytes, however, we observed unbalanced changes in
the expression of Ca2+ and K+ currents (Coppini et al., 2013).
As shown in Figure 1, we observed a reduction of the expression
of all K+ channels (including IKs) while the expression of
Ca2+ channels and the density of ICaL was slightly increased.
Therefore, in response to β-stimulation, the potentiation of ICaL
prevails over the increase of K+ currents, ultimately causing
a net increase of inward currents during the plateau of the
AP, thus determining a “paradoxical” prolongation of APD in
HCM cardiomyocytes (Ferrantini et al., 2018; Figures 5E,F).
Moreover, we observed that β-adrenergic stimulation in HCM
cardiomyocytes not only increased peak ICaL amplitude, but
also slowed down ICaL inactivation (Ferrantini et al., 2018;
Figures 5G,H), further contribute to the prolongation of APs
by β-adrenergic agonists. Additionally, recent work suggested
that β-adrenergic stimulation is able to rapidly and transiently
increase INaL in cardiac myocytes (Dybkova et al., 2014): a further
augmentation of the already increased INaL in HCM myocytes
may have played a relevant role in the paradoxical prolongation
of APs with isoprenaline. As expected, AP prolongation by
β-adrenergic agonists further increased the occurrence of
arrhythmogenic early afterdepolarizations, triggered activity and
spontaneous premature contractions in HCM cardiomyocytes
and trabeculae (Ferrantini et al., 2018). This paradoxical electrical
response may have severe consequences in HCM patients, that is,
it may increase the risk of exercise/stress-induced arrhythmias in
HCM patients.
In parallel, the response of HCM cardiomyocytes to
β-adrenergic stimulation in terms of Ca2+-handling changes
was also abnormal. In HCM cardiomyocytes the β-adrenergic-
induced increase of Ca2+ release may primarily rely on the
prolongation of Ca2+ entry via ICaL channels caused by the
slower current inactivation. In addition to the increase of net
Ca2+ influx through ICaL, the potentiation of Ca2+-entry via
reverse-mode NCX may have contributed to the augmentation
of Ca2+-transients β-receptor activation (Perchenet et al., 2000).
The increase of NCX-mediated Ca2+-entry upon β-adrenergic
stimulation is probably caused by the rise of intracellular [Na+] in
response to the transient augmentation of INaL and by the further
prolongation of AP plateau, as reverse-mode NCX is only active
at positive membrane potentials (Coppini et al., 2013; Dybkova
et al., 2014). The idea that the increase of contractile tension in
response to β-adrenergic activation mainly depends on the larger
Ca2+-entry through the sarcolemma apparently contrasts with
the largely accepted idea that the inotropic response of β-stimulus
mainly stems from the increase of SR Ca2+ content (Desantiago
et al., 2008), mediated by the enhancement of SR Ca2+-uptake
by SERCA via PKA-dependent phospholamban phosphorylation,
ultimately causing an enhanced release of Ca2+ from the SR.
The hastening of Ca-transient decay in response to isoprenaline
in HCM cardiomyocytes (Ferrantini et al., 2018) suggests that
the β-adrenergic-induced increase of SERCA function (via
PkA-mediated phospholamban phosphorylation) is preserved
in HCM myocardium, as Ca-transient decay is physiologically
accelerated by isoproterenol. Despite the shortening of Ca2+
transient decay, their rise-time is so prolonged that the total
duration of Ca2+-transients is not reduced upon β-stimulation.
The rise of SR Ca2+ load upon exposure to isoprenaline in
HCM myocytes may be limited by the increased phosphorylation
of ryanodine receptors (due to the higher CaMKII activity),
which in turn causes a larger rate of Ca2+ leakage from the SR
during the diastolic period. This may render positive inotropic
responses more dependent on the increase of Ca2+ entry from
the sarcolemma, as the possibility to accumulate Ca2+ in the SR
is limited. An additional contributor to this aberrant behavior is
the lower density of t-tubules observed in HCM myocytes (see
above) (Orchard and Brette, 2008). The physiological response
to β-adrenergic activation may be radically different in disease-
remodeled myocytes showing a sparse and disorganized the
T-tubular system. In HCM cells, where T-tubules are nearly
absent, we expect a large redistribution of ICaL channels to
the surface sarcolemma (Coppini et al., 2013). Under such
conditions, modulation of cellularinotropism essentially relies on
the magnitude of sarcolemmal Ca2+ triggers (Ferrantini et al.,
2014), that is, the amplitude and duration of ICaL plus the rate of
NCX-mediated Ca2+ entry (reverse mode). The prolongation of
APs causing increased sarcolemmal Ca2+-entry appears to be an
essential requisite for the preservation of the positive-inotropic
effect of β-adrenergic stimulation in HCM myocardium. In line
with that hypothesis, the application of ranolazine or GS-967 on
top of isoproterenol, which prevented the β-adrenergic-induced
AP prolongation, also greatly reduced the positive inotropic
response to β-stimulation in HCM myocardium (Ferrantini
et al., 2018). The preservation of inotropic response in HCM
myocardium comes at the expense of a further impairment
of diastolic function (due to prolonged Ca2+ transient rise-
time) and a further increase of the likelihood of cellular
arrhythmias (due to increased cytosolic Ca2+ accumulation and
AP prolongation).
CONCLUSION
Hypertrophic remodeling in the myocardium of patients with
HCM features several pathological alterations of cardiomyocyte
electrical function and intracellular Ca2+-handling (Figure 6),
that contribute to increase the likelihood of EADs, DADs and
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FIGURE 6 | Functional changes of ion currernts and EC-coupling in human HCM vs. control myocardium (CARTOON).
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premature contractions. Such arrhythmogenic changes occur
since the early stages of HCM disease development and
may explain the occurrence of ventricular arrhythmias and
cardiac arrest in young HCM patients who lack advanced
structural alterations of myocardial structure (e.g., diffuse
fibrosis, myocardial scars, massive hypertrophy, severe
microvascular abnormalities). Changes of the expression
and function of ion channels and EC-coupling proteins
in HCM myocardium concur to generate an “acquired
channelopathy” phenotype in HCM patients that raises the
risk of arrhythmias even before the establishment of a
structural substrate for sustained arrhythmias. Among the
several molecular determinants of cellular arrrhythmogenesis,
increased INaL appear to play a leading role in HCM
and may represent a selective target for pharmacological
prevention of arrhythmias in this disease, with possible
clinical implications. Although targeting INaL is proven to be
effective antiarrhytmic approach, one cannot discount NCX
(Passini et al., 2016), leaky RyR channels or cardiac CaMKII
as potential targets to reduce Ca2+-dependent arrhythmias
in HCM.
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